Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies

被引:26
|
作者
Aiebchun, Thitinan [1 ]
Mahalapbutr, Panupong [2 ]
Auepattanapong, Atima [3 ,4 ]
Khaikate, Onnicha [3 ,4 ]
Seetaha, Supaphorn [5 ]
Tabtimmai, Lueacha [6 ]
Kuhakarn, Chutima [3 ,4 ]
Choowongkomon, Kiattawee [5 ]
Rungrotmongkol, Thanyada [1 ,7 ]
机构
[1] Chulalongkorn Univ, Fac Sci, Dept Biochem, Biocatalyst & Environm Biotechnol Res Unit, Bangkok 10330, Thailand
[2] Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen 40002, Thailand
[3] Mahidol Univ, Fac Sci, Dept Chem, Bangkok 10700, Thailand
[4] Mahidol Univ, Fac Sci, Ctr Excellence Innovat Chem PERCH CIC, Bangkok 10700, Thailand
[5] Kasetsart Univ, Fac Sci, Dept Biochem, Bangkok 10900, Thailand
[6] King Mongkuts Univ Technol North Bangkok, Fac Appl Sci, Dept Biotechnol, Bangkok 10800, Thailand
[7] Chulalongkorn Univ, Fac Sci, Program Bioinformat & Computat Biol, Bangkok 10330, Thailand
来源
MOLECULES | 2021年 / 26卷 / 08期
关键词
EGFR tyrosine kinase; vinyl sulfone derivatives; in silico study; kinase assay; cytotoxicity assay; EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; MOLECULAR-DYNAMICS; FACTOR RECEPTOR; DECARBOXYLATIVE SULFONYLATION; ERLOTINIB RESISTANCE; POINT MUTATIONS; GEFITINIB; COMPLEX; ACIDS;
D O I
10.3390/molecules26082211
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Epidermal growth factor receptor (EGFR), overexpressed in many types of cancer, has been proved as a high potential target for targeted cancer therapy due to its role in regulating proliferation and survival of cancer cells. In the present study, a series of designed vinyl sulfone derivatives was screened against EGFR tyrosine kinase (EGFR-TK) using in silico and in vitro studies. The molecular docking results suggested that, among 78 vinyl sulfones, there were eight compounds that could interact well with the EGFR-TK at the ATP-binding site. Afterwards, these screened compounds were tested for the inhibitory activity towards EGFR-TK using ADP-Glo (TM) kinase assay, and we found that only VF16 compound exhibited promising inhibitory activity against EGFR-TK with the IC50 value of 7.85 +/- 0.88 nM. In addition, VF16 showed a high cytotoxicity with IC50 values of 33.52 +/- 2.57, 54.63 +/- 0.09, and 30.38 +/- 1.37 mu M against the A431, A549, and H1975 cancer cell lines, respectively. From 500-ns MD simulation, the structural stability of VF16 in complex with EGFR-TK was quite stable, suggesting that this compound could be a novel small molecule inhibitor targeting EGFR-TK.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] In Vitro and In Silico Studies of Kinase Inhibitor of MAPK3 Protein to Determine Leishmania martiniquensis Treatment
    Aiebchun, Thitinan
    Rasri, Natchaya
    Kiriwan, Duangnapa
    Siripattanapipong, Suradej
    Choowongkomon, Kiattawee
    ACTA PARASITOLOGICA, 2023, 68 (01) : 240 - 248
  • [42] Identification of the Brucea java']javanica Constituent Brusatol as a EGFR-Tyrosine Kinase Inhibitor in a Cell-Free Assay
    Suwattanasophon, Chonticha
    Mistlberger-Reiner, Agnes
    Alberdi-Cedeno, Jon
    Pignitter, Marc
    Somoza, Veronika
    Koenig, Juergen
    Lamtha, Thomanai
    Wanaragthai, Panatda
    Kiriwan, Duangnapa
    Choowongkomon, Kiattawee
    ACS OMEGA, 2023, 8 (31): : 28543 - 28552
  • [43] Treating pulmonary blastoma with EGFR tyrosine kinase inhibitor - a rare case report
    Jin, Bo
    Yang, Chun-Jiao
    Qiu, Xue-Shan
    Liu, Yun-Peng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (03): : 2730 - 2735
  • [44] Elucidation of Dietary Polyphenolics as Potential Inhibitor of Microtubule Affinity Regulating Kinase 4: In silico and In vitro Studies
    Khan, Parvez
    Rahman, Shafikur
    Queen, Aarfa
    Manzoor, Saaliqa
    Naz, Farha
    Hasan, Gulam Mustafa
    Luqman, Suaib
    Kim, Jihoe
    Islam, Asimul
    Ahmad, Faizan
    Hassan, Md. Imtaiyaz
    SCIENTIFIC REPORTS, 2017, 7
  • [45] EGFR - TYROSINE KINASE INHIBITOR AS FIRST LINE TREATMENT IN METASTATIC LUNG ADENOCARCINOMA
    Febriani, Anna
    Wulandari, Laksmi
    Hariadi, Slamet
    Wibisono, Yusuf
    RESPIROLOGY, 2010, 15 : 67 - 67
  • [46] Leukocytociastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib
    Boeck, S.
    Wollenberg, A.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2007, 18 (09) : 1582 - 1583
  • [47] Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
    Johnston, Stephen R. D.
    Leary, Alex
    DRUGS OF TODAY, 2006, 42 (07) : 441 - 453
  • [48] Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
    Montemurro, Filippo
    Valabrega, Giorgio
    Aglietta, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (02) : 257 - 268
  • [49] Cells expressing EGFR lacing C-terminal are still hypersensitive to EGFR tyrosine kinase inhibitor
    Maegawa, Mari
    Arao, Takuzo
    Matsumoto, Kazuko
    Kudo, Kanae
    Tanaka, Kaoru
    Kaneda, Hiroyasu
    Fujita, Yoshihiko
    Ito, Fumiaki
    Nishio, Kazuto
    CANCER RESEARCH, 2008, 68 (09)
  • [50] Identification of tumor microenvironment-based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
    Chen, Wenjie
    Li, Wen
    Liu, Zhenkun
    Ma, Guangzhi
    Deng, Yunfu
    Zhu, Lingling
    Zhou, Qinghua
    JOURNAL OF CANCER, 2022, 13 (03): : 877 - 889